2.

Univariate analysis of survival after first TACE and HAIC

Variables	MST (month)	Univariate analysis		P
		HR	95% CI
TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; PR, partial response; SD, stable disease; PD, progressive disease; OXA, oxaliplatin; 5-Fu, 5-fluorouracil; CF, calcium folinate; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; NA, not available.
Age (year) (>60vs. ≤60)	15.8vs. 15.4	0.937	0.664–1.323	0.712
Gender (malevs. female)	16.3vs. 13.0	0.788	0.549–1.131	0.196
Histology (poorlyvs. well and moderate)	16.7vs. 22.0	1.656	0.973–2.821	0.063
Primary tumor site (left sidevs. right side)	16.9vs. 11.4	0.767	0.499–1.181	0.229
Serum CA19-9 (U/mL) (≥37vs. <37)	12.5vs. 21.1	2.120	1.445–3.110	<0.001
Serum CA72-4 (U/mL) (≥6.7vs. <6.7)	13.5vs. 20.3	1.525	1.052–2.209	0.026
Serum CEA (U/mL) (≥5vs. <5)	14.4vs. 21.1	1.460	0.885–2.408	0.139
Extrahepatic metastasis (presentvs. absent)	19.2vs. 23.3	1.172	0.825–1.667	0.376
Time to liver metastasis (synchronousvs. metachronous)	14.8vs. 16.5	1.293	0.850–1.966	0.230
Largest size of metastases (cm) (≥5vs. <5)	13.1vs. 16.6	1.281	0.857–1.913	0.228
No. of metastases (singlevs. multiple)	27.4vs. 20.8	0.662	0.308–1.420	0.289
Treatment times of TACE and HAIC				0.183
≤2	11.6	1.447	0.974–2.149	0.068
2–4	12.7	1.233	0.793–2.149	1.233
≥5	19.9	1	1	NA
Other local treatment (combinedvs. uncombined)	21.1vs. 14.4	0.630	0.411–0.966	0.034
Response to TACE				<0.001
PR (29.0%)	21.1	0.242	0.150–0.390	<0.001
SD (45.7%)	16.6	0.305	0.197–0.472	<0.001
PD (24.7%)	7.8	1	1	NA
Embolization (yesvs. no)	21.7vs. 24.3	1.032	0.664–1.605	0.887
Tumor stain				0.157
Poor	16.5	0.941	0.712–1.245	0.672
Moderate	14.2	1.292	0.971–1.720	0.079
Well	13.0	1	1	NA
Infusion agents (OXA+5-Fu+CFvs. OXA+raltitrexed)	15.5vs. 16.5	1.002	0.592–1.696	0.994
Lipiodol deposit				0.162
Poor	21.1	0.831	0.387–1.785	0.635
Moderate	14.2	1.280	0.640–2.561	0.485
Well	17.6	1	1	NA